2026-04-23T22:38:47Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/2455-5452.000014 2016-09-20 PTZ.IJVSM:VOL2

The use of Cilostazol in Diabetic Patients Konstantinos SpanosAthanasios D GiannoukasThe International Diabetes Federation (IDF) reported that the global prevalence of diabetes (DM) in adults was 8.3% in 2013 expecting to rise beyond 592 million by 2035 with a 10.1% global prevalence [1]. Guidelines have been published for the treatment of this major disease and its complications [2,3]. Recently, cilostazol has been proposed for the treatment of diabetic patients and their complications. Cilostazol is a selective inhibitor of phosphodiesterase type 3 that appears to have both antiplatelet and anti-proliferative effects [4]. Cilostazol inhibits platelet aggregation in response to ADP, epinephrine, collagen and arachidonic acid, and suppresses the production of platelet derived endothelial cell growth factor [4]. International Journal of Vascular Surgery and Medicine - Peertechz Publications 2016-09-20 Editorial https://doi.org/10.17352/2455-5452.000014 en Copyright © Konstantinos Spanos et al.